Who Is Eligible for Spravato Treatment? A Clear, Clinician-Led Guide

Eligibility is one of the most important questions to answer before considering Spravato treatment. It is not a treatment that is appropriate for everyone, and determining whether someone qualifies involves more than a quick online search or self-assessment.

This guide explains who is eligible for Spravato treatment and how clinicians evaluate candidacy in real clinical settings. We’ll walk through the criteria providers look for, the medical and psychiatric factors that matter, and why careful screening is part of responsible depression care.

If you are considering Spravato and want help understanding whether you may be eligible, Charak Center for Health and Wellness can help guide that evaluation. Our clinicians take time to review symptoms, treatment history, and medical considerations so eligibility decisions are based on careful assessment, not guesswork.

What Spravato Is

Spravato is a prescription nasal spray medication approved by the FDA for adults with certain forms of depression. It contains esketamine, which is chemically different from traditional antidepressants and is used under strict medical supervision.

Response rates for Spravato are often reported around 50% or higher in patients with treatment-resistant depression (TRD). For this reason, it is administered in a certified clinical setting rather than taken at home. Each session includes monitored dosing and an observation period, and it is prescribed alongside an oral antidepressant as part of a structured treatment plan, not as a standalone medication.

Because of how it is regulated and administered, Spravato nasal spray treatment is considered a specialized option within depression care and requires careful clinical evaluation before use.

Core Eligibility Criteria for Spravato Treatment

Eligibility for Spravato is based on a combination of FDA approval guidelines and clinical judgment. Meeting one criterion alone is not enough. Providers look at diagnosis, treatment history, symptom severity, and overall clinical stability.

FDA-Approved Uses and Diagnostic Requirements

Spravato is FDA-approved for adults with specific forms of depression, including:

• Treatment-resistant depression (TRD), which affects an estimated 10–30% of people, is defined as depression that has not responded adequately to at least two different antidepressant medications taken at appropriate doses and durations.
• Major depressive disorder (MDD), which affects more than 280 million people worldwide, can present with acute suicidal ideation or behavior and, in this context, Spravato is used alongside an oral antidepressant as part of a closely monitored treatment approach.

In clinical terms, “treatment-resistant” does not mean that nothing has helped at all. It means prior antidepressant trials did not lead to sufficient or lasting improvement despite appropriate dosing and duration, a distinction clarified through ongoing clinical research in mental health treatment

Treatment History Considerations

Spravato is approved only for adults. It is not indicated for pediatric patients. Providers also review treatment history to confirm that standard options have been tried thoughtfully rather than briefly or inconsistently.

Eligibility typically requires:

• A documented history of trials with two or more antidepressants that did not provide adequate relief
• Ongoing use of, or willingness to take, a concomitant oral antidepressant
• A structured treatment plan that supports supervised, in-clinic care and ongoing monitoring

This review process helps ensure Spravato is considered as a medical treatment option only when it aligns with clinical evidence and patient safety.

Who Qualifies for Spravato Treatment

Spravato is intended for a specific group of patients. Eligibility is based on clinical criteria rather than preference alone, with a focus on safety, treatment history, and likelihood of benefit.

1. You are an adult with major depressive disorder

Spravato is approved for adults with a confirmed diagnosis of major depressive disorder made by a qualified mental health professional.

2. Your depression is treatment-resistant

This typically means depressive symptoms have not improved after trials of two or more antidepressants taken at appropriate doses and durations. Many eligible patients have experienced severe depression despite standard care.

3. You are taking, or willing to take, an oral antidepressant

Spravato is approved only when used alongside other antidepressants, not as a standalone therapy. Providers also review current medications to assess potential medication interactions.

4. You can participate in supervised, in-clinic treatment

Each treatment experience includes monitored dosing, an observation period, and safety checks. Patients must arrange transportation and avoid activities like driving or operating machinery on treatment days due to possible side effects such as feeling drunk or temporary dissociation.

5. You do not have medical conditions that increase risk

Clinicians assess factors such as increased blood pressure, certain heart conditions, and other health concerns before confirming eligibility. Ongoing risk evaluation and mitigation strategy protocols help ensure safety throughout the induction phase and beyond.

Taken together, these factors help clinicians determine who should be considered for Spravato treatment based on diagnosis, treatment history, and overall safety.

Who May Not Be Eligible or May Need Extra Caution

Spravato may not be appropriate, or may require additional evaluation, if any of the following apply:

• Uncontrolled high blood pressure or certain cardiovascular conditions that need stabilization before treatment.
• A history of specific neurological or vascular conditions that could increase risk during treatment.
• Moderate to severe liver impairment, which can affect how the medication is processed.
• Pregnancy or plans to become pregnant, requiring careful discussion of potential risks.
• A history of substance misuse that is not well managed, given Spravato’s controlled status.

In many cases, coordinating care across providers helps ensure treatment decisions remain aligned over time, which is often supported through structured case management services that focus on continuity rather than isolated interventions.

Evidence-Based Options When Spravato Isn’t Appropriate

Not qualifying for Spravato does not mean you are out of options. Eligibility decisions are based on safety and clinical fit, not on the severity or validity of your symptoms. Many effective treatments are available, and the right option depends on your diagnosis, history, and individual needs.

Medication Optimization or Adjustment

Prescription antidepressant medication bottle and weekly pill organizer on a table, representing medication management commonly used in the treatment of bipolar depression

This may involve revisiting the type, dosage, or combination of antidepressant medications under close psychiatric supervision. In some cases, small changes can lead to meaningful improvements when previous trials were limited by side effects or incomplete response.

Talk Therapy and Structured Psychotherapy

Evidence-based approaches such as cognitive behavioral therapy or trauma-informed therapy can play a central role in treatment, particularly when symptoms are influenced by thought patterns, stress, or past experiences. Therapy is often most effective when integrated into a broader care plan.

Transcranial Magnetic Stimulation (TMS)

TMS is a non-invasive, in-clinic treatment option that may be appropriate for people with treatment-resistant depression who do not meet criteria for Spravato. It is delivered under medical supervision and is often considered when medication-based approaches have not been effective.

Intensive Outpatient or Partial Hospitalization Programs

These programs provide more structured support when symptoms significantly interfere with daily functioning. They combine therapy, medication management, and clinical monitoring in a coordinated setting.

Collaborative Care and Case Management

Coordinated treatment plans that address medication, therapy, lifestyle factors, and medical concerns together can be especially helpful for complex or long-standing symptoms. This approach focuses on continuity and individualized care rather than a single intervention.

For many patients, the most effective path forward comes from matching treatment to the full clinical picture. A thorough evaluation helps identify the most appropriate next step, even when Spravato is not part of the plan.

Common Misconceptions About Spravato Eligibility

Misunderstandings about Spravato eligibility are common and can shape expectations before a clinical evaluation even takes place.

Misconception: Spravato Is Only for People in Immediate Crisis

Fact: Spravato is approved for treatment-resistant depression as well as major depressive disorder with acute suicidal ideation. It is not limited to emergency situations and may be considered outside of crisis care when symptoms persist despite standard treatment.

Misconception: Trying Many Medications Automatically Qualifies You

Fact: Eligibility is not based on the number of medications alone. Clinicians assess whether prior treatments were appropriate in dose, duration, and response, along with diagnosis and safety considerations.

Misconception: Spravato Is a One-Time or Short-Term Treatment

Fact: Spravato is not a single-session treatment. It follows a structured schedule that typically involves multiple sessions per week during an initial phase, followed by ongoing maintenance visits based on clinical response.

Misconception: Eligibility Decisions Are the Same for Everyone

Fact: While Spravato is regulated nationally, eligibility decisions are individualized. Medical history, current symptoms, and risk factors all influence whether treatment is appropriate for a specific patient.

Misconception: Not Qualifying Means There Are No Other Options

Fact: Not qualifying for Spravato does not mean treatment options are exhausted. Many people benefit from other evidence-based approaches when care is matched to their full clinical picture.

Clarifying these points helps patients approach eligibility discussions with more realistic expectations and better questions for their provider.

Making Sense of Spravato Eligibility

Spravato eligibility is less about meeting a single requirement and more about understanding how the treatment fits into a person’s overall mental health care. Diagnosis, treatment history, medical safety, and the ability to participate in structured care all play a role in that decision.

If you are considering Spravato and want help understanding whether it may be appropriate for you, Charak Center for Health and Wellness offers clinician-led evaluations grounded in your symptoms, treatment history, and overall health. To speak with our team, call 1-855-4CHARAK (1-855-424-2725) or fill out the contact form to request a consultation.

‍